Aprea Therapeutics Inc APRE

$0.49 -0.04 (-8.22%)

Valuation

Market cap
6,771,000
Revenue TTM
$290,000
Net income TTM
$-12,600,000
PE ratio
0.00
Forward PE
—
Profit margin
-4,344.83%
Debt to equity
0.00

Trading

Volume
171,000
Avg volume
382,416
Day's range
$0.49 – $0.54
Shares out
12,591,000
Stochastic %K
43%
Beta
1.66
Analysts
Strong Sell
Price target
$3.30

Price

Company profile

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers a...

Show more

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Industry
Biotechnology
Sector
Healthcare
Phone
215 948 4119
Website
https://aprea.com
Address
3805 Old Easton Road, Doylestown, United States

Latest news

Stocktwits

SNOWBALLDB321 Oct 29, 5:02 PM
$APRE This event presentation should move the needle for Aprea. Upcoming Presentation Details Event: 38th EORTC-NCI-AACR Symposium (ENA 2026) Topic: Interim results from the first-in-human Phase 1 study of WEE1 inhibitor APR-1051 in patients with advanced solid tumors (ACESOT-1051) Presenting Author: Dr. Timothy A. Yap (MD Anderson Cancer Center) Date and Time: Friday, November 20, 2026, from 3:00 PM to 3:10 PM CET
0 replies
SNOWBALLDB321 Oct 29, 4:53 PM
$APRE When Aprea Therapeutics successfully demonstrates that its synthetic lethality pipeline (combining its ATR inhibitor, ATRN-119, and its WEE1 inhibitor, APR-1051) matches the anti-tumor efficacy of AstraZeneca's historical WEE1 program (adavosertib) but without the severe toxicities of adavosertibthe, the stock market reaction will be highly dramatic, resulting in an asymmetrical shift in valuation for Aprea. Historically, AstraZeneca’s adavosertib demonstrated strong efficacy and tumor shrinkage. However, it failed and was discontinued in 2022 because of unacceptable toxicities like severe myelosuppression and GI complications. Delivering the same therapeutic punch without those flaws cracks open a massive market opportunity.
0 replies
Benny_Cellura Oct 28, 8:19 AM
$APRE ,,,
0 replies
Wolfie_Runs_Alone Oct 28, 2:59 AM
$APRE Been a while since there's been movement here. Must be time to grab a few and sit tight.
0 replies
Wolfie_Runs_Alone Oct 27, 7:34 PM
$APRE 👀
0 replies
focafoca99 Oct 16, 12:53 PM
$APRE hosts a virtual panel on WEE1 inhibition ahead of ESMO 2026 on Oct 20.
0 replies
SNOWBALLDB321 Oct 7, 1:29 PM
$APRE A positive clinical update for Aprea Therapeutics regarding their WEE1 inhibitor program at the upcoming EORTC-NCI-AACR Symposium in November 2026 carries major strategic, financial, and scientific significance: Validation of Differentiated WEE1 Inhibition: Earlier data already showed confirmed partial responses (such as in PPP2R1A-mutated endometrial cancer) with favorable tolerability and a lack of class-limiting toxicities seen with older WEE1 inhibitors. A positive update solidifies the thesis that APR-1051 has a superior therapeutic index and provides the green light and clinical backing to speed up enrollment and resource allocation. This oral presentation enhances institutional investor sentiment, strengthens capital-raising capabilities, and increases the likelihood of pharmaceutical licensing or co-development interest. Proving best-in-class potential for APR-1051 sets Aprea apart in the synthetic-lethality and DNA-damage response inhibitor space.
1 replies
xTheEi8htx Sep 30, 1:54 AM
Ei8ht Watchlist Premarket — 7:00–9:00 AM ET 1. $ALDX 2. $FFAI 3. $RNTX 4. $PMVP 5. $APRE
1 replies